Prices are updated after-hours

Manufacturing Treatment

KemPharm Inc

KMPH | $5.46 6.04% 0

|

(0.0% 1d) (0.7% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 188,396,547
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea treatment profitable

add to watch list Paper trade email alert is off

Greenbrook TMS Inc

GBNH | $0.121 -4.88% 6M

|

(0.0% 1d) (0.0% 1m) (-77.8% 1y) (-24.5% 2d) (-24.5% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 4,936,822
https://greenbrooktms.com
Sec Filling | Patents | n/a employees

Operating through 123 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared,non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 370,000 TMS treatments to close to 10,000 patients struggling with depression.

treatment

add to watch list Paper trade email alert is off

Intercure Ltd.

INCR | $2.43 -4.88% 28K

|

(0.0% 1d) (5.5% 1m) (24.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (200.76% volume)
Earnings Calendar: 2023-11-14
Market Cap: $ 109,675,533
https://www.intercure.co
Sec Filling | Patents | 2021 employees

Intercure Ltd operates as a cannabis company. The Company produces and distributes cannabis products for medical treatments. Intercure serves clients worldwide.

treatment msa

add to watch list Paper trade email alert is off

Mallinckrodt plc

MNKKQ | $0.02

|

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (10.5% 3d) (0.0% 7d) (-51.93% volume)
Earnings Calendar:
Market Cap:
http://www.mallinckrodt.com/
Sec Filling | Patents | 3085 employees

(IE) Mallinckrodt Pharmaceuticals is an Irish–tax registered manufacturer of specialty pharmaceuticals , generic drugs and imaging agents. In 2017 it generated 90% of sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar, was Medicaid's most expensive drug. Mallinckrodt acquires , manufactures, and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the acquisition, manufacture, and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products, and radiopharmaceuticals. The company employed 5,500 and had net sales of $3.2 billion in 2017; of which $2.9 billion was from the U.S. healthcare system.

diagnostics acquisitions treatment

add to watch list Paper trade email alert is off

Bright Minds Biosciences Inc

DRUG | $1.25 -6.61% 11K

|

(0.0% 1d) (7.8% 1m) (-56.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-81.0% volume)
Earnings Calendar:
Market Cap: $ 5,542,296
https://brightmindsbio.com
Sec Filling | Patents | 908 employees

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

treatment

add to watch list Paper trade email alert is off

Avalo Therapeutics Inc

AVTX | $13.175 7.9% 40K

|

(0.0% 1d) (152.3% 1m) (295.1% 1y) (0.0% 2d) (0.0% 3d) (1.7% 7d) (22.36% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 13,624,663
https://www.cerecor.com
Sec Filling | Patents | 31 employees

(United States) Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

monoclonal antibodies antibody covid respiratory treatment

add to watch list Paper trade email alert is off

ATAI Life Sciences N.V.

ATAI | $2.025 8.29% 590K

|

(0.0% 1d) (12.7% 1m) (-5.1% 1y) (0.0% 2d) (0.0% 3d) (-13.2% 7d) (4.42% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 336,203,452
https://www.atai.life
Sec Filling | Patents | 35 employees

(DE) atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London.

treatment profitable msa

add to watch list Paper trade email alert is off

Humacyte Inc

HUMA | $3.975 7.43% 720K

|

(0.0% 1d) (17.8% 1m) (8.8% 1y) (0.0% 2d) (0.0% 3d) (18.6% 7d) (-46.5% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 473,357,819
https://humacyte.com
Sec Filling | Patents | n/a employees

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

diabetic diabetes ceiling treatment defense t-cell

add to watch list Paper trade email alert is off

Hyperfine Inc - Class A

HYPR | $0.85 6.4K

|

(0.0% 1d) (-21.3% 1m) (-41.0% 1y) (0.0% 2d) (0.0% 3d) (-6.6% 7d) (-2.8% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 48,409,766
https://hyperfine.io
Sec Filling | Patents | 2 employees

Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the world’s first FDA-cleared portable MRI system. Hyperfine designed Swoop to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by a tablet. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments (ED), operating rooms (OR) outside the sterile field, and intensive care units (ICU), among others.

treatment msa eletrical

add to watch list Paper trade email alert is off

Icecure Medical Ltd

ICCM | $1.22 28K

|

(0.0% 1d) (2.1% 1m) (-9.0% 1y) (0.0% 2d) (0.0% 3d) (-5.4% 7d) (-18.8% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 55,660,589
https://icecure-medical.com
Sec Filling | Patents | n/a employees

Founded in 2006, Israel-based IceCure Medical develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally-invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide, after receiving FDA and CE approvals.

treatment cancer urea israel kidney lung cancer lungs

add to watch list Paper trade email alert is off

Imunon Inc

IMNN | $1.27 19K

|

(0.0% 1d) (41.1% 1m) (7.6% 1y) (0.0% 2d) (0.0% 3d) (11.4% 7d) (-30.57% volume)
Earnings Calendar:
Market Cap: $ 11,937,732
https://www.celsion.com
Sec Filling | Patents | 27 employees

(US) Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

vaccine treatment ovarian cancer cancer hepatitis

add to watch list Paper trade email alert is off

Inspira Technologies Oxy B.H.N. Ltd

IINN | $1.92 1.05% 11K

|

(0.0% 1d) (2.2% 1m) (65.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-32.46% volume)
Earnings Calendar:
Market Cap: $ 30,052,178
https://inspira-technologies.com
Sec Filling | Patents | 2021 employees

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology, which it believes will elevate and stabilize patient oxygen saturation levels. The Company's ART technology potentially allows patients to remain awake during treatment while minimizing the use of the highly invasive, risky and costly mechanical ventilation systems that require medically induced coma. The Company's products have not yet been tested or used in humans and has not approved by the U.S. Food and Drug Administration (FDA).

treatment blood sensors respiratory

add to watch list Paper trade email alert is off

YUMANITY THERAPEUTICS, INC.

KA A | $0.606 -4.55% 210K

|

(0.0% 1d) (13.4% 1m) (-84.2% 1y) (0.0% 2d) (0.0% 3d) (34.0% 7d) (67.77% volume)
Earnings Calendar:
Market Cap: $ 6,643,251
https://www.proteostasis.com
Sec Filling | Patents | 45 employees

(US) Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

treatment dementia biopharma com alzheimer's disease parkinson pharma arm drug candidate system ytx-7739 disease cel cov alzheimer's gen drug discovery parkinson's tiona alzheimer als rapid program therapeutics neurodegenerative pot phase 1 potential tempo sclerosis platform rap alzheimer’s

add to watch list Paper trade email alert is off

Lisata Therapeutics Inc

LSTA | $2.67 6.4K

|

(0.0% 1d) (-18.6% 1m) (-19.6% 1y) (0.0% 2d) (0.0% 3d) (-4.0% 7d) (-4.1% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 22,180,846
https://www.caladrius.com
Sec Filling | Patents | 24 employees

(US) Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

treatment msa kidney lungs t-cell covid

add to watch list Paper trade email alert is off

NRX Pharmaceuticals Inc

NRXP | $2.925 -2.5% 26K

|

(0.0% 1d) (466.0% 1m) (414.3% 1y) (0.0% 2d) (0.0% 3d) (-28.2% 7d) (-9.41% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 28,902,121
https://www.bigrockpartners.com/spac/spac_aboutus.html
Sec Filling | Patents | 2 employees

(US) Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Big Rock Partners' management team includes Richard Ackerman, Chairman, President, and Chief Executive Officer, and Bennett Kim, Chief Financial Officer, Chief Investment Officer, Corporate Secretary and Director.

covid treatment vaccine acquisitions zyesami aviptadil blank check

add to watch list Paper trade email alert is off

Novo Integrated Sciences Inc

NVOS | $0.5136 160K

|

(0.0% 1d) (4.3% 1m) (375.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-2.17% volume)
Earnings Calendar:
Market Cap: $ 9,786,403
https://www.novointegrated.com
Sec Filling | Patents | 92 employees

Novo Integrated Sciences, Inc. is a U.S. based provider of multidisciplinary primary care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science. The company believes that “decentralizing” healthcare, through the integration of medical technology and interconnectivity offers an essential solution to the fundamental transformation of healthcare delivery. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost- effective healthcare distribution. Currently, the Company’s revenue is generated solely through NHL’s team of multidisciplinary primary health care clinicians and practitioners providing assessment, diagnosis, treatment, pain management, rehabilitation, education and primary prevention for a wide array of orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations through NHL’s 16 corporate-owned clinics, a contracted network of affiliate clinics, and eldercare related long-term care homes, retirement homes, and community-based locations in Canada. Its specialized multidisciplinary primary health care services include, but are not limited to, physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy (including pre- and post-partum), acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women’s pelvic health programs, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning programs including event and game coverage, and private personal training.

diagnostics women treatment education games

add to watch list Paper trade email alert is off

Regencell Bioscience Holdings Ltd

RGC | $7.86 22.05% 17K

|

(0.0% 1d) (74.1% 1m) (-76.0% 1y) (0.0% 2d) (0.0% 3d) (35.9% 7d) (134.08% volume)
Earnings Calendar:
Market Cap: $ 102,281,127
https://www.regencellbioscience.com
Sec Filling | Patents | 2021 employees

Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. The Company started in Hong Kong in 2014 and completed its first research study using personalized TCM formula in Hong Kong. The Company aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients in Hong Kong first and subsequently to other markets.

treatment

add to watch list Paper trade email alert is off

NeuroPace Inc

NPCE | $14.235 1.68% 77K

|

(0.0% 1d) (7.4% 1m) (238.2% 1y) (0.0% 2d) (0.0% 3d) (1.8% 7d) (31.25% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 374,148,099
https://www.neuropace.com
Sec Filling | Patents | 167 employees

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy, and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

education treatment

add to watch list Paper trade email alert is off

Edgewise Therapeutics Inc

EWTX | $15.555 3.15% 72K

|

(0.0% 1d) (-5.8% 1m) (109.4% 1y) (0.0% 2d) (0.0% 3d) (-1.0% 7d) (-30.32% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 1,448,335,741
https://edgewisetx.com
Sec Filling | Patents | n/a employees

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

drug discovery treatment

add to watch list Paper trade email alert is off

GH Research PLC

GHRS | $12.135 3.54% 12K

|

(0.0% 1d) (11.1% 1m) (43.6% 1y) (0.0% 2d) (0.0% 3d) (6.6% 7d) (6.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 631,361,540
https://www.ghres.com
Sec Filling | Patents | 2021 employees

(IE) GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.

treatment

add to watch list Paper trade email alert is off

← Previous
1
2
Next →

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.595 164.08% 13M

|

AGBA | $2.61 108.8% 41M

|

CZOO | $9.32 86.77% 18M

|

EDBL | News | $6.7 78.19% 1.7M

|

MTC | $2.28 46.15% 2.6M

|

Technology Services

OPRT | News | $3.14 39.56% 7.6M

|

VNRX | $0.8 33.33% 2.9M

|

Health Technology

MLEC | $1.865 33.21% 2.4M

|

PALI | $6.37 29.21% 21M

|

LOCL | $3.33 27.59% 43K

|

Last 48 Hours Insiders Buying

HNVR | $16.35 800

|

| 16:30
VUZI P 34500 | $1.375 1.85% 280K

|

Electronic Technology

| 16:00
TPL P 3 | $584.65 -0.2% 7.4K

|

| 15:00
ETST P 79000 | $0.065 110K

|

| 11:30
MCFT P 26039 | $21.57 0.33% 46K

|

Consumer Durables

| 00:00
YORW P 29 | $35.655 0.66% 18K

|

| 19:01
BANF P 256 | $92.28 1.1% 17K

|

| 15:30
RMCF | $3.57 170

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar